Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply

EORTC CATNON investigators

doi:10.1016/s1470-2045(21)00418-6

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply

EORTC CATNON investigators

Neurology

Research output: Contribution to journal › Article › Professional › peer-review

Original language	English
Pages (from-to)	e346
Journal	The Lancet Oncology
Volume	22
Issue number	8
DOIs	https://doi.org/10.1016/s1470-2045(21)00418-6
Publication status	Published - 1 Aug 2021

Bibliographical note

Funding Information:
MJvdB reports grants from the Dutch Cancer Foundation, Brain Tumor Charity, Strijd van Salland, and Merck Sharp & Dohme (formerly Schering Plough), during the conduct of the study; and personal fees from Carthera, Nerviano, Bayer, Cellgene, Agios, AbbVie, Karyopharm, Boston Pharmaceuticals, and Genenta, outside the submitted work. MT declares no competing interests.

Access to Document

10.1016/s1470-2045(21)00418-6

Cite this

@article{8e5063eef924484dbbb0e7415b1ebe79,

title = "Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply",

author = "{EORTC CATNON investigators} and {van den Bent}, {Martin J.} and Mircea Tesileanu",

note = "Funding Information: MJvdB reports grants from the Dutch Cancer Foundation, Brain Tumor Charity, Strijd van Salland, and Merck Sharp & Dohme (formerly Schering Plough), during the conduct of the study; and personal fees from Carthera, Nerviano, Bayer, Cellgene, Agios, AbbVie, Karyopharm, Boston Pharmaceuticals, and Genenta, outside the submitted work. MT declares no competing interests.",

year = "2021",

month = aug,

day = "1",

doi = "10.1016/s1470-2045(21)00418-6",

language = "English",

volume = "22",

pages = "e346",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply

AU - EORTC CATNON investigators

AU - van den Bent, Martin J.

AU - Tesileanu, Mircea

N1 - Funding Information: MJvdB reports grants from the Dutch Cancer Foundation, Brain Tumor Charity, Strijd van Salland, and Merck Sharp & Dohme (formerly Schering Plough), during the conduct of the study; and personal fees from Carthera, Nerviano, Bayer, Cellgene, Agios, AbbVie, Karyopharm, Boston Pharmaceuticals, and Genenta, outside the submitted work. MT declares no competing interests.

PY - 2021/8/1

Y1 - 2021/8/1

UR - http://www.scopus.com/inward/record.url?scp=85111489967&partnerID=8YFLogxK

U2 - 10.1016/s1470-2045(21)00418-6

DO - 10.1016/s1470-2045(21)00418-6

M3 - Article

AN - SCOPUS:85111489967

SN - 1470-2045

VL - 22

SP - e346

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 8

ER -

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply

Bibliographical note

Access to Document

Other files and links

Cite this